Background: Preclinical assays of affective and sensorial aspects of nociception play a key role in research on both the neurobiology of pain and the development of novel analgesics. Therefore, we investigated the effects of nicotine and alpha-7 nicotinic acetylcholine receptor (nAChR) modulators in the negative affective and sensory components of visceral pain in mice. Methods and Results: Intraperitoneal acetic acid (AA) administration resulted in a robust stretching behaviour and conditioned place aversion (CPA) in mice. We observed a dose-dependent reduction in AA-induced stretching and CPA by the nonselective nAChRs agonist nicotine. Mecamylamine, a nonselective nAChRs agonist, was able to block its effects; however, hexamethonium, a peripherally restricted nonselective nicotinic antagonist, was able to block nicotine's effect on stretching behaviour but not on CPA. In addition, systemic administration of a7 nAChR full agonists PHA543613 and PNU282987 was failed to block stretching and CPA behaviour induced by AA. However, the a7 nAChRpositive allosteric modulator PNU120596 blocked AA-induced CPA in a dose-dependent manner without reducing stretching behaviours. Conclusions: Our data revealed that while nonselective nAChR activation induces antinociceptive properties on the sensorial and affective signs of visceral pain in mice, a7 nAChRS activation has no effect on these responses. In addition, nonselective nAChR activationinduced antinociceptive effect on stretching behaviour was mediated by central and peripheral mechanisms. However, the effect of nonselective nAChR activation on CPA was mediated centrally. Furthermore, our data suggest a pivotal role of allosteric modulation of a7 nAChRS in the negative affective, but not sensory, component of visceral pain. Significance: The present results suggest that allosteric modulation of a7 nAChR may provide new strategies in affective aspects of nociception.
Introduction
Pain is a complex experience which has been described as a multidimensional state composed of sensory, affective and cognitive components (Apkarian et al., 2004; Neugebauer et al., 2009; Ji et al., 2010) . In addition, clinical intervention of pain is often accompanied by changes in affective behaviours (Joshi and Honore, 2006; Hummel et al., 2008; Mogil, 2009; Whiteside et al., 2013) . Recent preclinical behavioural studies suggest that these affective aspects of pain can be evaluated in rodents, such as depression of positively reinforced operant responding maintained by delivery of food (Martin et al., 2004) or electrical brain stimulation (Do Carmo et al., 2009; Leitl et al., 2014) in injury or noxious stimuli-related pain. Similarly, intraplantar injection of complete Freund's adjuvant-induced affective pain state could be measured in rats by conditioned place aversion (CPA) test (Johansen et al., 2001; Zhang et al., 2013) . In addition, we recently reported that mouse model of chemotherapy-induced allodynia come along with negative affective-related symptoms, including anxiety-and depression-like behaviours . We and others also showed that an affective component of pain could be assessed in visceral pain-induced aversion in the CPA test following intraperitoneal (i.p.) injection of acetic acid (AA) in rodents (Deyama et al., 2010; Bagdas et al., 2016a ). An i.p. injection of AA results stretching (or 'writhing') response which is commonly used as a behavioural endpoint in studies of visceral pain elicited (Koster et al., 1959) . However, the stretching response is an example of a 'pain-stimulated behaviour' which can be defined as a behaviour that increases in rate, frequency or intensity after delivery of a noxious stimulus (Negus et al., 2006 (Negus et al., , 2010 . Although preclinical models of pain are largely performed by measuring reflexive responses to noxious stimuli to investigate the sensory aspect of pain, the affective pain aspect is equally important (Li, 2013) . Assessing only reflexive outcomes can be problematic because they are sensitive not only to treatments that reduce sensory sensitivity to the noxious stimulus, but also to treatments that produce motor impairment. Therefore, we recently adapted the AA test in the mouse and reported it as a useful tool to assess the antinociceptive properties of investigational drugs for differentiation of reflexive and affective behaviours (Bagdas et al., 2016a) . For example, while the opioid analgesic morphine and the NSAID ketoprofen reverses both AA-induced stretching and CPA, kappa agonist U50,488H blocks stretching but not AAinduced CPA (Bagdas et al., 2016a) . Therefore, complementary use of procedures which measure sensory and affective behaviours may increase predictive validity in translational research with candidate analgesics (Bagdas et al., 2016a) .
Nicotinic acetylcholine receptors (nAChRs) have been explored for the past three decades as a strategy for pain control. These receptors are widely expressed throughout the central and peripheral nervous system as well as immune cells. Despite encouraging results with many selective a4b2* agonists in animal models of pain, human studies showed a narrow therapeutic window between analgesic efficacy, and toxicity is associated with the use of these agonists as analgesics (for a recent review see Damaj et al., 2014) . However, several recent developments have potentially opened new windows of opportunity in the use of nicotinic agents for analgesia. Accumulating evidences suggest that agonists and modulators for a7 nAChRs hold a lot of promise in the treatment of pain conditions . Therefore, in this study, we evaluated the pharmacological modulation of AA stimulus-induced stretching and CPA in mice by a7 nAChRs ligands and compared it to that of nicotine, a prototypical nicotinic agonist.
Materials and methods

Animals
Male adult ICR mice obtained from Harlan Laboratories (Indianapolis, IN, USA) were used throughout the study. Mice (25-30 g) were 10-12 weeks of age at the start of the experiments and were grouphoused in a 21°C humidity-controlled Association for Assessment and Accreditation of Laboratory Animal Care-approved animal care facility with ad libitum access to food and water. The rooms were on a 12-hour light/dark cycle (lights on at 7:00 a.m. . All other drugs were dissolved in physiological saline and injected at a total volume of 1 ml/100 g body weight unless noted otherwise. All test drugs with the exception of AA and PNU120596 were injected subcutaneously (s.c.); AA and PNU120596 were administered intraperitoneally (i.p.). All doses are expressed as the free base of the drug.
Acetic acid-induced stretching
The AA-induced stretching test was carried out in a Plexiglas box (29 9 19 9 13 cm each), and mice were allowed to acclimate for 20 min in the test cage prior to AA injection. As we described previously (Bagdas et al., 2016a) , mice were treated with i.p. 1.2% AA or vehicle, and the number of stretches was counted in 10-min bins for 60 min. A stretch was operationally defined as a contraction of the abdomen followed by an extension of the hindlimbs.
To evaluate test drug effects on sensorial signs of visceral pain via stretching test, mice were pretreated with vehicle of test drugs, the nonselective nAChR agonist nicotine (0.1, 0.32, 1 mg/kg; 5 min pretreatment), the a7 nAChR full agonist PHA543613 (4, 12 mg/kg; 15 min pretreatment), the a7 nAChR full agonist PNU282987 (10, 20 mg/kg; 15 min pretreatment) or the a7 nAChR PAM PNU120596 (1, 3, 9, 12 mg/kg; 15 min pretreatment) prior to i.p. injection of 1.2% AA, and observation began immediately after AA injection. In a separate experiment, to test the role of nAChRs in the effect of nicotine, the nonselective nAChR antagonist mecamylamine (2 mg/kg) and hexamethonium (1 mg/kg), the peripherally restricted nonselective nicotinic antagonist, were used 10 min prior nicotine (1 mg/kg) injection in the stretching test. Each mouse was used for only one experiment. Nicotine (Freitas et al., 2015) , PHA543613 (Freitas et al., 2013a) , PNU282987 (Freitas et al., 2015) , PNU120596 (Freitas et al., 2013a,c) , mecamylamine (Kyte et al., 2018) and hexamethonium (Damaj et al., 1999; Jackson et al., 2009 ) doses were selected based on our previous studies.
Acetic acid (AA)-induced conditioned place aversion (CPA) studies
CPA was determined according to a validated, unbiased design as we previously described (Bagdas et al., 2016a) . In brief, separate groups of mice were handled for 3 days prior to initiation of conditioning. The CPA apparatus (ENV3013; Med-Associates, St. Albans, VT, USA) consisted of white and black chambers (20 9 20 9 20 cm each), which differed in floor texture (white mesh and black rod). The compartments were separated by a smaller grey chamber with a smooth PVC floor and partitions that allowed access to the black and white compartments. The black and white compartments also had different floor textures, and removable doors separated the centre grey compartment from the two white and black side compartments. Experiments were conducted using a 3-day protocol. On day 1, mice were placed in the grey centre compartment for a 5-min habituation period followed by a 15-min test period to determine baseline time spent in each compartment by removing the doors. A prepreference score was recorded, and mice within each group were then randomly assigned such that an even number of mice received the experimental treatment on the black and white side. On day 2, the doors were in place to separate the compartments, and mice were exposed to two 40-min conditioning sessions no less than 4 h apart. Prior to one conditioning session, mice received one of the treatments described below and were placed into either the black or white compartment as dictated by their assignment on day 1. Prior to the other conditioning session, mice received vehicle injections and were placed into the other compartment. On day 3, the doors were again removed after habituation, and the day 1 procedure was repeated.
To evaluate test drug effects on affective signs of visceral pain via CPA test, mice were pretreated with vehicle of test drugs, nicotine (0.1, 0.32, 1 mg/kg; 5 min pretreatment), PHA543613 (4, 12 mg/kg; 15 min pretreatment), PNU282987 (10, 20 mg/kg; 15 min pretreatment) or PNU120596 (1, 3, 9, 12 mg/kg; 15 min pretreatment) prior to i.p. injection of 1.2% AA or sterile water as vehicle of AA. In a separate experiment, to test the role of nAChRs in the effect of nicotine, mecamylamine (2 mg/kg) and hexamethonium (1 mg/ kg) were used 10 min prior nicotine (0.1 mg/kg) injection in CPA test. Treatment conditioning sessions began immediately after AA/vehicle injection.
Data were expressed as time in seconds spent in the treatment-paired compartment postconditioning minus time spent in that compartment preconditioning. A positive number indicated a treatment-induced place preference, whereas a negative number indicated a treatment-induced place aversion.
Statistical analysis
The data obtained were analysed using the GraphPad software, version 6.0 (GraphPad Software, Inc., La Jolla, CA, USA) and expressed as the mean AE SEM. Statistical analysis of all test drugs effects in behavioural studies was performed using one-way analysis of variance (ANOVA) with Dunnet's post hoc correction when appropriate. Post hoc test was used in two steps to compare the mean of each column with the mean of a control column according to vehicle-vehicle treatment or vehicle-AA treatment. An additional Dunnet's post hoc comparison was done for mecamylamine and hexamethonium. Before ANOVA, the data were first assessed for the normality of the residuals and equal variance. Variances were similar between groups and were assessed using either the F test or the Brown-Forsythe test and the Bartlett's test. All data passed these tests. The p values < 0.05 were considered significant. ED50 values with 95% CL for behavioural data were calculated by unweighted least-squares linear regression as described by Tallarida and Murray (1987) .
Results
3.1 Nicotine blocked AA-induced stretching and CPA Figure 1A shows that AA-stimulated stretching was dose-dependently blocked by nicotine (F 4,25 = 13.09; p < 0.001). AA at the concentration of 1.2% stimulated visceral pain in mice as seen significant writhing responses (p < 0.001). While 0.1 mg/kg dose of nicotine had no effect on AA-induced stretching, higher doses (0.32 and 1 mg/kg) attenuated writhing behaviour. Nicotine at the dose of 1 mg/kg fully blocked stretches. In addition, nicotine did not stimulate stretching in the absence of acid treatment.
Similar to the stretching test results, nicotine pretreatments reversed the AA-induced CPA in a doserelated manner (F 7,50 = 13.75; p < 0.001) (Fig. 1B) . AA (1.2%) induced a robust CPA as seen negative preference to AA-paired chamber on conditioning days (p < 0.001). While 0.001 mg/kg dose of nicotine had no effect on AA-induced CPA, higher doses (0.01, 0.1 and 0.32 mg/kg) totally inhibited CPA response. In addition, the analysis of time spent in drug-paired side of the test compartment for nicotine doses in control mice did not show place preference or aversion (p > 0.05). Thus, nicotine selectively attenuated the AA-induced CPA.
The potency of nicotine in blocking AA-induced stretching and CPA are expressed as ED50 values and are shown in Table 1 .
The effects of nicotine on AA-induced behaviours are mediated by nAChRs
One-way ANOVA revealed significant effects for the antagonist pretreatments in AA-induced stretching test (F 8,57 = 32.79; p < 0.001). Nicotine (1 mg/kg) reversed writhing responses (p < 0.001). As shown the effects of nicotine (1 mg/kg) in Fig. 1C , mecamylamine and hexamethonium blocked the antinociceptive effects of nicotine in stretching test (p < 0.001).
Moreover, significant effects by antagonist pretreatments were also found in CPA test (F 8,55 = 10.68; p < 0.001) (Fig. 1D) . Nicotine (0.1 mg/kg) was able to totally block AA-induced CPA (p < 0.001). In addition, mecamylamine pretreatment prior to nicotine injection fully blocked the effects of nicotine on CPA (p < 0.001). However, hexamethonium could not attenuate the effect of nicotine on CPA (p > 0.05). The analysis of time spent in drug-paired side of the test compartment for mecamylamine and hexamethonium in saline control mice did not show place preference or aversion (p > 0.05), which reveals that mecamylamine and hexamethonium have no effect on its own. Furthermore, mecamylamine and hexamethonium pretreatments had no effect on AA-induced CPA by itself (p > 0.05).
3.3 The a7 nAChR agonists, PHA543613 and PNU282987 failed to block AA-induced stretching and CPA Figure 2 shows the effects of pretreatments with a7 nAChR agonists PHA543613 and PNU282987 on AA-induced writhing and aversion. One-way ANOVA revealed significant effects for PHA543613 and AA treatments in stretching test (F 3,20 = 91.2; p < 0.001, Fig. 2A ) and CPA test (F 4,35 = 21.38; p < 0.001, Fig. 2B ). However, as shown the effects of PHA543613 (4 and 12 mg/kg) in Fig. 2A and B, AAinduced stretching and CPA behaviour were not altered by PHA543613 pretreatments, respectively (p > 0.05).
The testing of an another a7 nAChR agonist, PNU282987 revealed similar results in both measures. One-way ANOVA revealed significant effects for PNU282987 and AA treatments in stretching test (F 3,22 = 14.3; p < 0.001, Fig. 2C ) and CPA test (F 5,33 = 5.743; p < 0.001, Fig. 2D ). In consistent with PHA543613, AA-induced writhing and aversion responses were not changed by PNU282987 (10 and 20 mg/kg) pretreatments, respectively (p > 0.05).
3.4 The a7 nAChR PAM, PNU120596, had no effects on AA-induced stretching but blocked AA-induced CPA Figure 3A shows that one-way ANOVA revealed significant effects for PNU120596 and AA treatments in stretching test (F 5,32 = 8.96 ; p < 0.001). However, post hoc analysis showed that PNU120596 (1, 3, 9 and 12 mg/kg) produced no significant reduction in AAinduced stretching (p > 0.05). Besides, PNU120596 reversed the CPA effect of AA in a dose-dependent manner (F 7,53 = 8.258; p < 0.001, Fig. 3B ). Although all doses of PNU120596 reduced AA-induced CPA, it totally blocked aversion at dose of 12 mg/kg (p < 0.001). In addition, the analysis of time spent in drug-paired side of the test compartment for PNU120596 doses in control mice did not show place preference or aversion (p > 0.05). Thus, PNU120596 AA, acetic acid; mec, mecamylamine; hex, hexamethonium. selectively attenuated the AA-induced CPA with an ED50 value of 6.01 (3.36-10.75) mg/kg (Table 1) .
Discussion
Our results indicate that systemic nicotine administration dose-dependently blocked the stretching and aversive behaviours of AA injection in mice. Furthermore, mecamylamine, a nonselective nicotinic antagonist, was able to block both nicotine-induced reversal of stretching and CPA, while the peripherally restricted antagonist hexamethonium blocked only the effects of nicotine on stretching. In addition, a7 nAChRS activation by full agonists PHA543613 and PNU282987 had no significant effect on the AA-stimulated stretching and CPA responses. However, positive allosteric modulation of a7 nAChRS by PNU120596 resulted in the total blockade of CPA but not stretching behaviours. We used a model of acute visceral pain, i.p. injection of AA, to compare the potency of nicotine in blocking nociceptive reflex behaviour and place aversion. We have previously demonstrated that nicotine can be antinociceptive in several mouse models of Figure 2 The effects of a7 nicotinic acetylcholine receptor full agonists PHA543613 and PNU282987 on AA-induced stretching and conditioned place preference (CPA). (A) Subcutaneous (s.c.) pretreatment of PHA543613 (4 and 12 mg/kg) failed to reduce 1.2% AA-induced stretching behaviour. (B) PHA543613 (4 and 12 mg/kg, s.c.) also failed to block AA-induced CPA. (C) PNU282987 (10 and 20 mg/kg, s.c.) was not able to reverse AA-induced stretching. (D) PNU282987 (10 and 20 mg/kg, s.c.) also failed to reduce AA-induced CPA. Data are expressed as means AE SEM from six to nine mice. Asterisks indicate a significant effect compared to associated vehicle by one-way ANOVA followed by Dunnet's post hoc test (*p < 0.05). veh, vehicle; AA, acetic acid; PHA: PHA543613.
pain (Damaj et al., 1998; Bagdas et al., 2015a Kyte et al., 2018 ). In our current study, nicotine was found to be more potent (27-fold) in alleviating the aversive state than the stretching responses induced by AA injection. While a low dose of nicotine (0.01 mg/kg) was sufficient to completely block the AA-induced CPA, a much higher dose (1 mg/kg) was needed to block AA-induced stretching. Our results are similar to those recently reported with nicotine which was found to be more potent in reversing intracranial self-stimulation deficit compared to stretching after i.p. injection of lactic acid in rats (Freitas et al., 2015) . The difference in nicotine potency is intriguing and suggests that the drug may act on different nicotinic mechanisms to block CPA and stretching. nAChRs are widely distributed throughout the body and brain (Changeux et al., 1998; Paterson et al., 2000) , with many different receptor subtype combinations, which can contribute to nicotine's diverse effects, ranging from analgesia to reward (Damaj et al., 1998; Walters et al., 2006; Pons et al., 2008; Rowley and Lu, 2008; Jackson et al., 2009; Freitas et al., 2013a,c) .
To determine if the effects of nicotine on AAinduced stretch behaviour and CPA were centrally or peripherally mediated, we used hexamethonium and mecamylamine, two nonselective nAChR antagonists. These antagonists did not alter AA responses on their own, but they prevented nicotine-induced reversal of AA-induced stretches. Interestingly, mecamylamine prevented nicotine reversal of AA-induced CPA, whereas hexamenthonium did not. Unlike hexamethonium, mecamylamine is blood-brain-barrier permeable (Liu et al., 2002; Hawkins et al., 2005) . This suggests that nicotine reversal of CPA, an affective component of pain, is mediated via central nervous system (CNS) mechanisms, whereas nicotine reversal of stretching is primarily mediated by peripheral mechanisms. Differences in nAChR subtypes, expression levels or availability (Schwartz and Kellar, 1983; Picciotto et al., 2000) in brain regions and peripheral nerves involved in processing the pain stimuli (Garland, 2012) or pain aversion (Hayes and Northoff, 2012) could explain why CPA and stretching behaviour did not respond equally to nicotine receptor ligands.
One of the nAChRs that was shown to play a role in inflammation and nociception is the a7 nAChR subtype. Several a7 agonists have been shown to reduce mechanical and thermal hypersensitivity in a number of animal models of chronic pain (Feuerbach et al., 2009; Loram et al., 2012; Freitas et al., 2013b) . We used the AA model of acute visceral pain to determine the role of a7 nAChRs in nociceptive reflex behaviour and aversive behaviour. For that, we investigated the effects of a7 agonists, PNU282987 and PHA543613, and the a7 PAM type II, PNU120596, in AA-induced stretching and CPA. Both a7 agonists were not able to reduce AA-stimulated stretching or CPA behaviour. This lack of activity is not very surprising as a7 nAChR agonists mostly lack efficacy in acute pain tests in rodents (Freitas et al., 2013a; Papke et al., 2015; Bagdas et al., 2016b) . In contrast, the a7 PAM dose-dependently reversed AA-induced CPA, without modifying stretching behaviour. That stretching behaviour was unaffected by the PAM suggests that a7 PAMs could be a new target to alleviate the aversive signs of pain. The contrast between a7 agonists and PAMs in the AA visceral pain test suggest a possible role for nAChRs desensitization. Indeed, a7 receptors undergo rapid desensitization upon agonist binding and adopt stable nonconducting (desensitized) conformations (Papke et al., 2009; Williams et al., 2011) . However, the type II PAMs such as PNU120596 can prevent normal desensitization and can even reactivate desensitized a7 nAChRs (Grøn-lien et al., 2007) .
The lack of effects of a7 receptors agonists in the AA acute visceral pain test is in contrast to their effects in more chronic pain models. Indeed, doses of PNU282987 and PHA543613 that were sufficient to reverse stimulus-evoked chronic pain behaviours in other models (Freitas et al., 2013b (Freitas et al., ,c, 2015 Donvito et al., 2017) , the a7 agonists did not reduce AA-stimulated stretching or CPA behaviour. In contrast, the a7 PAM dose-dependently reversed AA-induced CPA, without modifying stretching behaviour. This suggests that the PAM is able to act on the aversive component of pain, without altering the motor response to visceral pain. In addition, the a7 PAM, PNU120596 did not produce preference or aversion on its own in sham mice, suggesting that it will have low abuse potential. In line of our results, we recently reported that 3-furan-2-yl-N-p-tolyl-acrylamide, a type II a7 PAM and GAT107, a a7-selective dual allosteric agonist and PAM, were active in the AA test (Bagdas et al., 2015b (Bagdas et al., , 2016b .
In conclusion, studies with mecamylamine and hexamethonium suggest that CNS nAChRs mediate nicotine-induced reversal of AA-induced CPA. Furthermore, the PAM studies suggest that a7 nAChRs allosteric modulation attenuate pain aversion, despite lack of reduction in stretching behaviour.
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